About
Resalis Therapeutics is a biotechnology company based in Turin, Italy, with connections to Aalborg University in Denmark and Harvard Medical School. The company specializes in RNA-based therapies aimed at treating complex metabolic disorders, particularly obesity and fatty liver disease. Their lead product candidate, RES-010, is an antisense oligonucleotide designed to inhibit the microRNA miR-22, which plays a crucial role in various metabolic pathways. RES-010 is being developed as a novel therapeutic option for obesity and metabolic-associated fatty liver disease (MAFLD), including metabolic-associated steatohepatitis (MASH). This treatment aims to reprogram metabolic pathways, potentially leading to sustained weight loss and fat reduction in key areas of the body. Currently, RES-010 is in Phase 1 clinical trials, with plans to advance to Phase 2 trials. Resalis Therapeutics targets patients with obesity and metabolic liver diseases, addressing significant unmet medical needs. The company collaborates with healthcare providers and pharmaceutical partners to enhance treatment options in this area, supported by strategic investments, including one from Sanofi.
Technologies
Keywords
Company Information
- Employees10
- Founded2020
Location
Paris, Ile-de-France, France
